AIM： To study the prognostic factors for intrahepatic cholangiocarcinoma （ICC） and evaluate the impact of chronic hepatitis B virus （HBV） infection on survival rate of ICC patients. METHODS： A total of 155 ICC p...AIM： To study the prognostic factors for intrahepatic cholangiocarcinoma （ICC） and evaluate the impact of chronic hepatitis B virus （HBV） infection on survival rate of ICC patients. METHODS： A total of 155 ICC patients who underwent macroscopic curative resections （R0 and R1） were enrolled in this retrospective study and divided into group A with HBV infection and group B without HBV infection according to their chronic HBV infection, represented by positive hepatitis B surface antigen （HBsAg） in serum or in liver tissue. Clinicopathological characteristics and survival rate of the patients were evaluated. RESULTS： All patients underwent anatomical resection. Their 1- and 3-year survival rates were 60.6% and 32.1%, respectively. Multivariate analyses revealed that HBV infection, hepatolithiasis, microscopic satellite lesion, and lymphatic metastasis were the independent prognostic factors for the survival rate of ICC patients. The median disease-free survival time of the patients was 5.0 too. The number of tumors, microscopic satellite lesion, and vascular invasion were the independent prognostic factors for the disease-free survival rate of the patients. The prognostic factors affecting the survival rate of ICC patients with HBV infection and those without HBV infection were not completely consistent. Alkaline phosphatase 〉 119 U/L, microscopic satellite lesion, vascular invasion, and lymphatic metastasis were the independent factors for the patients with HBV infection, while r-glutamyltransferase 〉 64 U/L, microscopic satellite lesion, and poor tumor differentiation were the independent factors for the patients without HBV infection. CONCLUSION： HBV infection is a valuable clinical factor for predicting tumor invasiveness and clinical outcome of ICC patients. ICC patients with HBV infection should be distinguished from those without HBV infection because they have different dinicopathological characteristics, prognostic factors and outcomes after surgical resection.展开更多
AIM： To assess whether CCL2 or interactions between this chemokine and its receptor （CCR2） are associated with outcomes of chronic hepatitis C and with responses to antiviral therapy. METHODS： Two hundred and eigh...AIM： To assess whether CCL2 or interactions between this chemokine and its receptor （CCR2） are associated with outcomes of chronic hepatitis C and with responses to antiviral therapy. METHODS： Two hundred and eighty-four patients with chronic hepatitis C and 193 non-infected matched controls were included in this study. Patients were categorized according to their Scheuer score of hepatic fibrosis as F0-F2 （/7 = 202） or F3-F4 （/7 = 82） and according to their response to anti-Hepatitis C virus （HCV） therapy as sustained response （SR, n = 201） or non-sustained response （NSR, n = 98）. Genotyping of the -2518 （A/G） CCL2 was performed using PCR-RFLP, genotyping of the 190 （A/G） CCR2 using a PCR-ARMS system, and genotyping of the rs3138042 （G/A） CCR2 using Taqman probes. RESULTS： Univariate analyses identified 4 parameters （infection duration time, viral genotype, gender and AST levels） that tended to influence fibrosis and 7 parameters （CCL2G, CCL2ACCR2A, viremia levels, fibrosis stage, viral genotype, infection duration time and AST levels） that significantly influenced or tended to influence response to treatment. Multivariate analysis identified gender and AST levels as parameters that independently influenced fibrosis stage and viral genotype and infection duration time were the two parameters that independently influenced response to treatment. CONCLUSION： Our results indicate that the mutations studied in the gene pair CCL2/CCR2 do not play a major role in the outcome and response to treatment for HCV infection in the Spanish population.展开更多
文摘AIM： To study the prognostic factors for intrahepatic cholangiocarcinoma （ICC） and evaluate the impact of chronic hepatitis B virus （HBV） infection on survival rate of ICC patients. METHODS： A total of 155 ICC patients who underwent macroscopic curative resections （R0 and R1） were enrolled in this retrospective study and divided into group A with HBV infection and group B without HBV infection according to their chronic HBV infection, represented by positive hepatitis B surface antigen （HBsAg） in serum or in liver tissue. Clinicopathological characteristics and survival rate of the patients were evaluated. RESULTS： All patients underwent anatomical resection. Their 1- and 3-year survival rates were 60.6% and 32.1%, respectively. Multivariate analyses revealed that HBV infection, hepatolithiasis, microscopic satellite lesion, and lymphatic metastasis were the independent prognostic factors for the survival rate of ICC patients. The median disease-free survival time of the patients was 5.0 too. The number of tumors, microscopic satellite lesion, and vascular invasion were the independent prognostic factors for the disease-free survival rate of the patients. The prognostic factors affecting the survival rate of ICC patients with HBV infection and those without HBV infection were not completely consistent. Alkaline phosphatase 〉 119 U/L, microscopic satellite lesion, vascular invasion, and lymphatic metastasis were the independent factors for the patients with HBV infection, while r-glutamyltransferase 〉 64 U/L, microscopic satellite lesion, and poor tumor differentiation were the independent factors for the patients without HBV infection. CONCLUSION： HBV infection is a valuable clinical factor for predicting tumor invasiveness and clinical outcome of ICC patients. ICC patients with HBV infection should be distinguished from those without HBV infection because they have different dinicopathological characteristics, prognostic factors and outcomes after surgical resection.
基金Supported by Plan Andaluz de Investigacion (PAI, grupos CTS-0197 and CTS-0102)Fundacion Reina Mercedes. MA Montes-Cano is the recipient of a fellowship from Instituto de Salud Carlos III (04/0146)
文摘AIM： To assess whether CCL2 or interactions between this chemokine and its receptor （CCR2） are associated with outcomes of chronic hepatitis C and with responses to antiviral therapy. METHODS： Two hundred and eighty-four patients with chronic hepatitis C and 193 non-infected matched controls were included in this study. Patients were categorized according to their Scheuer score of hepatic fibrosis as F0-F2 （/7 = 202） or F3-F4 （/7 = 82） and according to their response to anti-Hepatitis C virus （HCV） therapy as sustained response （SR, n = 201） or non-sustained response （NSR, n = 98）. Genotyping of the -2518 （A/G） CCL2 was performed using PCR-RFLP, genotyping of the 190 （A/G） CCR2 using a PCR-ARMS system, and genotyping of the rs3138042 （G/A） CCR2 using Taqman probes. RESULTS： Univariate analyses identified 4 parameters （infection duration time, viral genotype, gender and AST levels） that tended to influence fibrosis and 7 parameters （CCL2G, CCL2ACCR2A, viremia levels, fibrosis stage, viral genotype, infection duration time and AST levels） that significantly influenced or tended to influence response to treatment. Multivariate analysis identified gender and AST levels as parameters that independently influenced fibrosis stage and viral genotype and infection duration time were the two parameters that independently influenced response to treatment. CONCLUSION： Our results indicate that the mutations studied in the gene pair CCL2/CCR2 do not play a major role in the outcome and response to treatment for HCV infection in the Spanish population.
